EU7-14550-99625
4 vaccinations
9 coded responses
54 check-ins
8 free-text entries
4 call cases
- Sex
- Female
- Age at first dose
- 61-65
- ZIP prefix
- 773 / TX
- Registered
- 2021-01-25
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-24
Dose 1 — Moderna
-
2021-01-25
Registered in v-safe
- 2021-01-25
- 2021-01-26
- 2021-01-27
- 2021-01-28
- 2021-01-29
- 2021-01-30
- 2021-01-31
- 2021-02-07
- 2021-02-14
-
2021-02-21
Dose 2 — Moderna
- 2021-02-21
-
2021-02-22
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain, Redness · Chills, Headache · Be unable to do your normal daily activitiesAdult check-in
-
2021-02-23
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain, Redness · HeadacheAdult check-in
- 2021-02-24
- 2021-02-25
- 2021-02-26
- 2021-02-27
- 2021-02-28
-
2021-03-07
Survey response — day 14, dose 2MedDRA: Conjunctivitis, Vision blurred — Feeling: Good · Be unable to do your normal daily activitiesFree text: Worsening conjunctivitis and blurry vision.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-14
Survey response — day 21, dose 2MedDRA: Conjunctivitis — Feeling: Good · Be unable to do your normal daily activitiesFree text: conjunctivitis (may be due to allergies)MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-21
Survey response — day 28, dose 2MedDRA: Conjunctivitis — Feeling: Good · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: conjunctivitis (possibly due to allergies)MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-21
Report sent to call center — day 28, dose 2Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-03-28
Survey response — day 35, dose 2MedDRA: Conjunctivitis, Seasonal allergy — Feeling: GoodFree text: Conjunctivitis (likely due to seasonal allergies)MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-04-04
Survey response — day 42, dose 2MedDRA: Conjunctivitis — Feeling: Good · Be unable to do your normal daily activitiesFree text: conjunctivitis (continues worsening, probably due to seasonal allergies)MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-05-23
Survey response — 3 months, dose 2MedDRA: Autoimmune disorder, Eye inflammation, Uveitis — Feeling: Fair · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: Panuveitis (actually started 2 weeks after 1st dose, but only recently diagnosed), a serious inflammation of both eyes. Autoimmune condition, which I am wondering if it could be associated with the vaccination.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-05-23
Report sent to call center — 3 months, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-08-23
Survey response — 6 months, dose 2MedDRA: Pulmonary embolism — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, HospitalizationFree text: Pulmonary embolismsMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-08-23
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr1 call case(s)
- 2021-08-25
- 2021-08-27
-
2021-08-30
Call successfulParticipant prefers to complete VAERS report online
-
2021-10-28
Dose 3 — Moderna
- 2021-10-28
- 2021-10-29
- 2021-10-30
- 2021-10-31
- 2021-11-01
- 2021-11-02
- 2021-11-03
- 2021-11-04
-
2021-11-11
Survey response — day 14, dose 3MedDRA: Migraine — Feeling: FairFree text: Migraine headachesMedDRA releases: 2024-11 · check-in free text available
- 2021-11-18
- 2021-11-25
- 2021-12-02
- 2021-12-09
- 2022-01-27
-
2022-04-05
Dose 4 — Moderna
- 2022-04-05
- 2022-04-06
- 2022-04-07
- 2022-04-08
- 2022-04-09
- 2022-04-10
- 2022-04-11
- 2022-04-12
- 2022-04-19
- 2022-04-26
- 2022-05-05
- 2022-05-12
- 2022-05-17
- 2022-07-05
- 2022-10-04
-
2023-04-05
Survey response — 12 months, dose 4MedDRA: Blindness, Macular degeneration, Macular oedema, Office visit, Pain, Visual impairment, Vitreous floaters — Feeling: Good · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professionalMedDRA releases: 2024-11
-
2023-04-05
Report sent to call center — 12 months, dose 4Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2023-04-06
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-24 | Moderna | |
| 2 | 2021-02-21 | Moderna | |
| 3 | 2021-10-28 | Moderna | No |
| 4 | 2022-04-05 | Moderna | No |
Call center
4 call center cases
4 successful
Free text
Release 5 — day 14, dose 2
Symptoms: Worsening conjunctivitis and blurry vision.
Release 5 — day 21, dose 2
Symptoms: conjunctivitis (may be due to allergies)
Release 6 — day 28, dose 2
Symptoms: conjunctivitis (possibly due to allergies)
Release 6 — day 35, dose 2
Symptoms: Conjunctivitis (likely due to seasonal allergies)
Release 6 — day 42, dose 2
Symptoms: conjunctivitis (continues worsening, probably due to seasonal allergies)
Release 8 — 3 months, dose 2
Symptoms: Panuveitis (actually started 2 weeks after 1st dose, but only recently diagnosed), a serious inflammation of both eyes. Autoimmune condition, which I am wondering if it could be associated with the vaccination.
Release 9 — 6 months, dose 2
Symptoms: Pulmonary embolisms
Release 10 — day 14, dose 3
Symptoms: Migraine headaches
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Office visit | · | · | ✓ |
| SD | Autoimmune disorder | ✓ | ✓ | ✓ |
| SD | Blindness | · | · | ✓ |
| SD | Conjunctivitis | ✓ | ✓ | ✓ |
| SD | Eye inflammation | ✓ | ✓ | ✓ |
| SD | Macular degeneration | · | · | ✓ |
| SD | Macular oedema | · | · | ✓ |
| SD | Migraine | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Pulmonary embolism | ✓ | · | ✓ |
| SD | Seasonal allergy | ✓ | ✓ | ✓ |
| SD | Uveitis | ✓ | ✓ | ✓ |
| SD | Vision blurred | ✓ | ✓ | ✓ |
| SD | Visual impairment | · | · | ✓ |
| SD | Vitreous floaters | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release